Author(s): Jin Cailing, Zhao Shupeng, Yang Jun, Chen Meiling, Kang Xiaochun, Niu Hongrui, Zhang Min
Pages: 24-27
Year: 2017 Issue:  11
Journal: Chinese Journal of Practical Nervous Diseases
Keyword:  Glioma; Intensity modulated radiothempy; Recombinant human endostatin; Temozolomide capsule;
Abstract: Objective To investigate the clinical efficacy and safety of recombinant human endostatin combined radiotherapy and chemotherapy for high-grade gliomas.Methods Totally 80 cases of brain glioma from January 2012 to December 2014 in the First Hospital of Xinxiang Medical College were divided into control group and observation group,40 cases in each group.The control group adopted radiotherapy combined with temozolomide chemotherapy,observation group applied recombinant human endostatin based on the control group.The patients were followed up for 2 years,and the objective curative effect and the safety of drugs were evaluated.Results The effective rate of the control group and the observation group were 45% and 70%,respectively,the difference was statistically significant (P<0.05).The one-year and two-year survival rate was 50%,35% and 72.5%,62.5%,respectively.The difference of survival rate between two groups was statistically significant (P<0.05).The adverse reactions were mostly from gradeⅠto grade Ⅱ.No grade Ⅲ or more adverse reactions were observed.There was no significant difference on adverse reactions (P>0.05).Conclusion Recombinant human endostatin combined radiotherapy and chemotherapy for high grade gliomas can significantly improve the short-and long-term clinical efficacy with a certain safety.It was worth for further clinical study.